retatrutide study news produces up to 30.3% weight loss in Phase 3 trial Use of an unapproved triple-hormone

GLP-1 medications work by mimicking glucagon-like peptide-1, a hormone that signals fullness and reduces hunger

FDA generally treats injectable products as drugs under the FDCA

International pharmaceutical companies and domestic healthcare manufacturers are establishing comprehensive distribution and manufacturing capabilities to address growing market demand for advanced diabetes care solutions

The $245 per month negotiated price demonstrates that dramatic price reductions are possible when a large payer negotiates from a position of volume

May be particularly useful given the pathogenesis-based rationale (NRTI-induced mitochondrial toxicity)